August 17, 2021 -- Eli Lilly has divided Lilly Bio-Medicines into neuroscience and immunology business units. The company said the move will help it introduce "breakthrough medicines" to people who need them.
Lilly Neuroscience will be led by Senior Vice President and Lilly Oncology President Anne White. White will be responsible for Lilly's products and phase III portfolio in pain and neurodegeneration, including the potential launch of donanemab for the treatment of Alzheimer's disease, according to the company.
Patrik Jonsson has been tapped as president of Lilly Immunology, managing Lilly's products and phase III portfolio of medicines in dermatology, gastroenterology, and rheumatology, the company said. He will retain his current roles as senior vice president and president of Lilly USA, as well as chief customer officer.
In addition, current Loxo Oncology CEO Jacob Van Naarden has been promoted to senior vice president and CEO of Loxo Oncology at Lilly, as well as president of Lilly Oncology. Van Naarden will unify these organizations and join Lilly's executive committee.
In other executive announcements, Lilly International Senior Vice President and President Alfonso Zulueta will retire from Lilly after more than 30 years of service. Zulueta will be succeeded by Ilya Yuffa, who is currently senior vice president and president of Lilly Bio-Medicines. Yuffa, a nearly 25-year Lilly veteran, will lead Lilly's commercial operations in all markets outside of the U.S., except for Canada.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
